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Although  the  majority  of  MDS  patients  fail  to achieve  clinical  improvement  to approved  therapies,  some
patients  beneﬁt  from  treatment.  Predicting  patient  response  prior  to  therapy  would  improve  treatment
effectiveness,  avoid  treatment-related  adverse  events  and  reduce  healthcare  costs.  Three  separate  cohorts
of MDS  patients  were  used  to simulate  drug  response  to lenalidomide  alone,  hypomethylating  agent
(HMA)  alone,  or HMA plus  lenalidomide.  Utilizing  a computational  biology  program,  genomic  abnor-
malities  in  each  patient  were  used  to create  an intracellular  pathway  map  that  was  then  used  to screen
for drug  response.  In the  lenalidomide  treated  cohort,  computer  modeling  correctly  matched  clinical
responses  in  37/46  patients  (80%).  In the  second  cohort,  15  HMA  patients  were  modeled  and  correctly
matched  to responses  in  12  (80%).  In the third  cohort,  computer  modeling  correctly  matched  responses
in  10/10  patients  (100%).  This  computational  biology  network  approach  identiﬁed  GGH  overexpressionma
enalidomide
as  a potential  resistance  factor to HMA  treatment  and  paradoxical  activation  of  beta-catenin  (through
Csnk1a1  inhibition)  as a resistance  factor  to  lenalidomide  treatment.  We  demonstrate  that  a  computa-
tional  technology  is  able  to  map  the complexity  of  the  MDS  mutanome  to simulate  and  predict  drug
response.  This  tool  can  improve  understanding  of MDS  biology  and  mechanisms  of drug  sensitivity  and
resistance.
© 2016  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-NDAbbreviations: MDS, myelodysplastic syndromes; AML, acute myeloid leukemia;
ZA, azacitidine; DEC, decitabine; LEN, lenalidomide; HI, hematological improve-
ent; SKY, spectral karyotyping; CNV, copy number variation; IWG, International
orking Group; HMA, hypomethylating agent; PPV, positive predictive value; NPV,
egative predictive value; CR, complete response; PR, partial response.
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1. Introduction
The myelodysplastic syndromes (MDS) comprise a group
of hematological malignancies characterized by ineffective
hematopoiesis causing severe cytopenias, multiple genomic and
epigenomic abnormalities, and progression to acute myeloid
leukemia (AML). Molecular heterogeneity exists among MDS
patients and is believed to cause variability in the syndromic
phenotype and treatment response [1]. Only three drugs are
approved by the U.S. Food and Drug Administration for MDS
patients: azacitidine (AZA), decitabine (DEC), and lenalidomide
(LEN). Despite these treatment options, failure to achieve hemato-
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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ogical improvement (HI) is found in 60% of MDS  patients treated
ith azacitidine or decitabine and 33% of deletion 5q (del(5q))
DS  patients [2,3]. No other standard therapies currently exist
ollowing failure of ﬁrst line treatment, and as a result, nearly
ll MDS  patients die of refractory disease [4,5]. Thus, there is a
arge unmet clinical need for (1) accurately predicting response
o ﬁrst line treatment and (2) identifying alternative therapies for
on-responders.
Several investigators have identiﬁed single gene mutations
ssociated with treatment response. For example, MDS  patients
ith mutations in TET2 or DNMT3A mutation were more likely to
chieve clinical improvement after HMA  treatment [6–8]. In del(5q)
DS  patients, the presence of a TP53 mutation was associated with
elative resistance to lenalidomide treatment [9]. Whereas, these
tudies represent important incremental advances, the observa-
ions rely upon one-gene/one-drug analysis and censor tens to
undreds of other genomic abnormalities that co-exist within the
DS  mutanome.
Therefore, we  hypothesized that use of a computational biology
echnique that incorporates the totality of known genomic abnor-
alities and their predicted protein network disruptions would
rovide strong correlations with clinical outcome in MDS.
. Materials and methods
.1. Patients
The three MDS  patient cohorts examined in this retrospective
tudy were prospectively recruited to interventional treatment tri-
ls or institutional patient registries, where all patients consented
o have tissue samples banked [6,9,10]. Their de-identiﬁed data
ere accessed via publication downloads or shared by investi-
ators. This retrospective study was approved by University of
lorida’s Institutional Review Board protocol IRB201602096.
.2. Computational biology modeling
The computational biology computer modeling system uti-
ized in this study was previously outlined and published
n studies of glioblastoma multiforme and multiple myeloma
11–13]. Based on over 10 000 published PubMed references,
his model considers signaling pathway interactions important
n cancer including growth factor signaling cascades, cytokines,
hemokines, mTOR regulators, cell cycle regulators, oxidative
nd ER stress responses, cancer metabolism, autophagy and pro-
eosomal degradation, DNA damage repair, apoptosis cascades
nd p53 signaling to predict a patient’s response to a single
rug or a combination of drugs. This modeling system includes
ore than 4 700 intracellular pathway elements that are capable
f simulating 60 000 functional interactions, including compre-
ensive coverage of the kinome, transcriptome, proteome, and
etabolome.
In this study, each MDS  patient’s available genomic informa-
ion (i.e., cytogenetic abnormalities and DNA sequencing data)
as entered into the computational biology system, which uti-
ized PubMed, STRING, HumanNet, and PathwayCommons online
esources to determine whether the patient’s gene mutation gen-
rated an activated or inactivated protein.
To interpret the genomic signature of the patient, we
sed cytogenetic proﬁling by spectral karyotyping (SKY) to
eport chromosomal aberrations, including gain/loss of complete
hromosomes or speciﬁc chromosomal regions resulting in mono-
omy/trisomy of the genes in the affected regions. In addition to
eletions and duplications, other abnormalities such as deriva-
ive chromosomes, isochromosomes, and translocations may  beResearch 52 (2017) 1–7
incorporated into the system. Additionally, targeted gene panel
sequencing or whole exome sequencing data can report copy num-
ber variations (CNV) and point mutation information that make
up the genomic signature of each patient’s disease. The genomic
aberration information derived from cytogenetics and sequencing
data is used to create a list of genes with mutations and CNV in
the patient’s genome. The genes found on the loci of the affected
regions of the chromosomes are extracted from the human refer-
ence genome at ENSEMBL, and the complete list of genes is matched
with the Cancer Technology Network to determine the subset of
genes to be represented in the model.
Key assumptions are made when indicating the aberrations
in each patient’s disease network: gain of function or ampliﬁ-
cation of tumor promoter genes, and loss of tumor suppressor
genes drives cancer [14]. Gene variants with therapeutic impli-
cations are searched using public domain to determine each
mutation’s functionality, represented as either a loss or gain of
function. However, genes with mutations of unknown signiﬁcance
are parsed through a suite of variant calling algorithms to deter-
mine if the mutation is deleterious. For a deleterious mutation
of unknown signiﬁcance, a tumor promoter gene is assumed to
have gain of function while a tumor suppressor gene is assumed
to have loss of function at the protein activity level. Frameshift
and missense mutations are assumed to cause a loss of gene func-
tion.
For CNV interpretation, ampliﬁcations are represented as an
increase of gene expression while deletions are represented as
knockdown of gene expression. Additionally, ampliﬁcations of
tumor suppressor genes have lower contribution to the disease
when compared to ampliﬁcation of tumor promoter genes. A dele-
tion of tumor suppressor genes has a higher dominance in the
disease network when compared to deletion of tumor promoter
genes.
Protein network maps were created for each patient based
on their MDS  mutanome data. In most cases, when multiple
genomic abnormalities co-exist, a complex map of intersecting
protein networks was created that represented the MDS  patient’s
disease physiology. Using the patients’ maps, cell proliferation
was simulated for each patient’s disease (Fig. 1). The prolif-
eration index is an average function of the active CDK-cyclin
complexes that deﬁne cell cycle checkpoints, and is determined by
calculating permutations in the biomarkers CDK4-CCND1, CDK2-
CCNE, CDK2-CCNA, and CDK1-CCNB1. The drug(s) of interest (e.g.,
AZA, DEC, LEN, AZA + LEN) were then introduced at various con-
centrations (i.e., C, 0.5C, and 4C) using relevant in vitro data
reported in PubMed. If the drug’s target and downstream mediators
were present, then decreases in cell proliferation were observed
(Fig. 1).
A viability index based on survival and apoptosis is also gen-
erated for each patient. The biomarkers constituting the survival
index include AKT1, BCL2, MCL1, BIRC5, BIRC2, and XIAP, while
the apoptosis index includes BAX, CASP3, NOXA, and CASP8. The
overall viability index of a cell is calculated as a ratio of survival
index/apoptosis index, and the weightage of each biomarker is
adjusted to achieve a maximum correlation with the experimen-
tal trends for the endpoint. The virtual patient disease network is
created by overlaying the patient’s genomic signature onto the con-
trol network, as per the rules and assumptions stated earlier, and
running it thought the simulation technology to achieve a dynamic
disease state.
If MDS  cell growth characteristics (proliferation, viability, apo-
ptosis) normalized in a dose dependent manner, then the patient’s
disease was  scored as responsive (Fig. 1). If the drug in the MDS
model did not decrease cell proliferation or viability, then the dis-
ease was scored as non-responsive.
L. Drusbosky et al. / Leukemia 
Fig 1. Cell Proliferation Simulation.
A simulation model is used to model the proliferative capacity of each patient’s
disease. This particular graph represents an MDS  patient sensitive to lenalidomide
treatment. The X-axis represents the elapsed time from mutation acquisition to
time  of treatment; the Y-axis represents the proliferation index (100% symbolizes
symptomatic disease state). Doses of selected drugs can be incorporated into the
model to simulate treatment and predict the cell’s response to therapy. The red line
denotes a half-dose of treatment, and reduces cell proliferation by 20%. The green
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line represents the established clinical concentration for the drug, and reduces cell
roliferation by 40%. The blue line represents a dose 4 times the clinical concentra-
ion, and reduces cell proliferation by 60%.
.3. Statistical analyses
To determine the extent by which computer modeled predic-
ions of drug sensitivity signiﬁcantly linked with actual clinical
esponse, we utilized association analyses of each independent
ariable of interest with each of the patient clinical outcomes. This
nalysis was carried out using Fisher’s Exact Test. P values < 0.05
ere statistically signiﬁcant.
. Results
.1. Del(5q) MDS  cohort
A total of 52 patients conﬁrmed to have del(5q) MDS  were
reated with LEN (Table 1) [9]. Conventional G-banding cytoge-
etics, single nucleotide polymorphism arrays (SNP-A) and gene
equencing of 6 recurrently mutated myeloid genes (TET2, ASXL1,
DH1, IDH2, TP53, CBL) were used to molecularly characterize each
atient. Clinical response to treatment was assessed using Interna-
ional Working Group (IWG) response criteria revised in 2006 [15].
ll patients received a minimum of two cycles of LEN and responses
ere evaluated after four cycles of treatment. Of the 52 del(5q)
DS  patients treated with LEN, 46 with both clinical outcomes and
vailable genomic data were included (Fig. 2A).
Fig. 2B shows a simpliﬁed schematic of dysregulated protein
etworks in one of the correctly predicted responders to LEN treat-
ent. Lenalidomide is known to interact with the E3 ubiquitin
igase cereblon (CRBN), which forms a complex with Cullin-4A
CUL4A), damaged DNA binding protein 1 (DDB1), and regulator
f cullins 1 (ROC1) [16]. Lenalidomide has been shown to target
his enzyme and alter is activity [17]. The computational tech-
ique projected that a patient’s chromosome del(5q) abnormality
aused a knockdown of IRF1, NR3C1 and ARHGAP26. The model-
ng software further predicted this chromosomal abnormality to
ause a dominant NFkB pathway that is effectively targeted through
enalidomide redirection of CRBN. Of note, it was discovered inResearch 52 (2017) 1–7 3
the computational biology model that lenalidomide paradoxically
upregulated beta-catenin, a known resistance factor for lenalido-
mide therapy, through inhibition of CSNK1A1. This observation
was inferred by the computational model, which was informed by
Pubmed literature that CSNK1 could be regulated by CRBN. The
model then made the connection between the drug and the target,
identifying the feedback to CSNK1.
Conversely, Fig. 2C is a 2-D schematic of a correctly predicted
non-responder, which displays a more complex network of pro-
tein perturbations. In addition to the known gene knockdowns
resulting from del(5q), this patient also showed knockdowns of
down-regulators of beta-catenin signaling (APC, CTNNA1, CDH1),
which predicted dominance in this resistance pathway. Addition-
ally, the CHMP1A knockdown was predicted to decreases TP53
activity, thereby weakening the intended targeted pathway of
lenalidomide and suggesting drug resistance.
In the clinical trial, 37/46 patients achieved clinical response to
LEN as deﬁned by CR or HI according to IWG  2006 criteria and 33/37
were correctly matched using the computational biology modeling
system, yielding a test sensitivity of 89% (p = 0.03586). Nine out of
46 patients did not respond to LEN treatment and 4/9 were cor-
rectly matched using the computational biology modeling system,
yielding a test speciﬁcity of 44%. Therefore, the positive predictive
value (PPV) of the computational biology system for the cohort of
del(5q) MDS  patients was  87%, the negative predictive value (NPV)
was 50%, and the overall test accuracy was  80%.
3.2. HMA  Cohort
A total of 213 MDS  patients were treated with an HMA  (AZA or
DEC) (Table 1) [6]. A subset of 15 patients with abnormal karyotype
was randomly selected for this study. Conventional cytogenetics
and next-generation sequencing of 40 recurrently mutated myeloid
genes were used. Clinical response to treatment was  assessed using
IWG  criteria revised in 2006 [15].
Of the 15 patients, 7 achieved response as deﬁned by CR, PR
or HI to HMA  treatment and 7/7 were correctly matched using
the computational biology modeling system, yielding a test sen-
sitivity of 100%. Of the 8 patients who did not respond to HMA
treatment, 5 were correctly matched, yielding a test speciﬁcity of
63% (p = 0.02564). Therefore, the PPV for this cohort of higher-risk
MDS  patients treated with HMAs was 70%, the NPV was  100%, and
the overall test accuracy was 80%.
Fig. 3B shows a simpliﬁed 2D schematic of a responder patient’s
dysregulated protein networks. As a hypomethylating agent, azac-
itidine efﬁcacy was predicted when a dominant methylation
pathway was present, as is seen through DNMT mediated CpG
methylation. The representative responder patient in Fig. 3B had a
loss of function of ASXL1, which was predicted to decrease methy-
lation and has previously been associated with lack of response
to therapy [18]. However, the patient’s downstream overexpres-
sion of EZH2 was predicted by the computational model to nullify
the loss of ASXL1 and allow methylation to persist as a target for
azacitidine.
In contrast, the non-responder MDS  patient shown in Fig. 3C
demonstrated a loss of ASXL1 and TET2, which was  predicted to
decrease PRC2-mediated function and DNMT recruitment for CpG
methylation. This is in agreement with the ﬁnding in Bejar et al.
that TET2 mutations do not serve as a marker for drug sensitiv-
ity if accompanied by an ASXL1 mutation [19]. Additionally, this
non-responder patient was predicted to have overexpression of
GGH, which inhibits S-adenosyl methionine synthesis required for
methylation, downregulating the methylation pathway, and tilt-
ing the balance towards non-response. This GGH  discovery in this
4 L. Drusbosky et al. / Leukemia Research 52 (2017) 1–7
Table 1
Patient Cohorts and Statistics.
Patient Cohort 1 2 3
Patients Modeled 46 15 10
Patients Excluded 6 98 26
MDS  Risk Category Low: 48%
Int-1: 50%
Int-2: 2%
High: 0%
Low: 13%
Int-1: 27%
Int-2: 40%
High: 20%
Low: 0%
Int-1: 10%
Int-2: 50%
High: 40%
Cytogenetic Abnormalities del(5q)+- other abnormalities Variety Variety
Treatment Lenalidomide 10 mg PO QD
D1-21 every 28-day cycle
Azacitidine 75 mg/m2  PO QD
daily 5–10 days for 21 days of a
28-day cycle or
Decitabine 20 mg/m2, IV on
days 1–5 of each 28 day cycle
Lenalidomide 5–10 mg PO QD
14–21 Days + Azacitidine
75 mg/m2  PO QD daily
5–10 days for 21 days of a
28-day cycle.
Patients who Achieved
Response (N, %)
37 (80%) 7 (46%) 8 (80%)
Patients Who  Did Not Achieve
Response (N, %)
9 (19%) 8 (53%) 2 (20%)
Correctly Predicted Responders
(N)
33 (89%) 7 (100%) 8 (100%)
Correctly Predicted
Non-Responders (N)
4 (44%) 5 (63%) 2 (100%)
Positive Predictive Value (%) 87% 70% 100%
Negative Predictive Value (%) 50% 100% 100%
Sensitivity/Speciﬁcity (%) 89%/44% 100%/63% 100%/100%
Prediction Accuracy 80% 80% 100%
P  value 0.03586 0.02564 0.022
Patient speciﬁc information for cohorts 1, 2 and 3, showing number of patients modeled, risk categories, cytogenetics, treatment and predicted response rates.
Fig. 2. Predictive percentages and two simpliﬁed 2-D schematics of a correctly predicted responder and non-responder from lenalidomide treated del[5]q patients.
Schematic of patients included in cohort 1, with 46/52 patients being modeled. 37/46 patients responded to lenalidomide treatment with 33/37 correctly predicted, giving
our  modeling system a test sensitivity of 89%. 9/46 patients did not respond to lenalidomide treatment with 4/9 correctly predicted, giving our modeling system a test
speciﬁcity of 44%. The PPV is 87%, NPV is 50%, and overall test accuracy is 80%. This analysis is statistically signiﬁcant (p = 0.03586), calculated using a Fisher’s Exact Test. B.
Simpliﬁed schematic of dysregulated protein networks in a positively predicted responder to lenalidomide treatment. Red lines show knockdown in patient proteins, dark red
lines  show knockdown from Lenalidomide treatment, blue lines show positive effects and black lines are normal protein networks. Lenalidomide induces ubiquination and
proteosomal degradation of CRBN resulting in the mapped downstream effects. Knockdown of IRF1, NR3C1 and ARHGAP26 are classic characteristics of del(5q) patients and
create  a dominant NFkB pathway that is effectively targeted through lenalidomide inhibition of CRBN. C. Simpliﬁed schematic of dysregulated protein networks in a correctly
predicted non-responder to lenalidomide treatment. In addition to the classic knockdown of del(5q) characteristics, there are knockdowns of beta-catenin signaling (APC,
CTNNA1, CDH1), causing dominance in this pathway. Additionally, the CHMP1A KD decreases activity of TP53, weakening the intended targeted pathway of lenalidomide
and  making this individual refractory to treatment
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Fig. 3. Two simpliﬁed schematics of a correctly predicted responder and non-responder from HMA  treated high-risk MDS  patients.
Schematic of patients included in cohort 2, with 15/213 patients being modeled. 7/15 patients responded to HMA  treatment with 7/7 correctly predicted, giving our modeling
system a test sensitivity of 100%. 8/15 patients did not respond to HMA  treatment and 5/8 was  correctly predicted, giving our modeling system a test speciﬁcity 63%.
Overall  PPV is 70%, NPV is 100%, and accuracy is 80%. This analysis is statistically signiﬁcant (p = 0.02564), calculated using a Fisher’s Exact Test. B. Simpliﬁed schematic of
dysregulated protein networks in a positively predicted responder to HMA  treatment. Red lines show knockdown in patient proteins, dark red lines show knockdown from
HMA  treatment, blue lines show positive effects and black lines are normal protein networks. Azacitidine efﬁcacy is facilitated by DNMT mediated CpG methylation. This
patient  has a knockdown of ASXL1 but overexpression of EZH2, which nulliﬁes the loss of ASXL1, indicating this patient would be susceptible to HMA  treatment. C. Simpliﬁed
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ediated function and DNMT recruitment for CpG methylation. Additionally, this
equired for methylation and tilts balance towards non-response.
atient was inferred from the computational model and represents
 novel ﬁnding to be validated.
.3. Azacitidine and lenalidomide cohort
A total of 36 high risk MDS  patients were enrolled in a phase I/II
tudy to evaluate the effectiveness of AZA and LEN in patients with
igher-risk MDS  (Table 1) [10]. Because clinical and genomic data
ere required for this computational technology, only 10/36 were
ligible for study (Fig. 4A). Clinical response to AZA and LEN treat-
ent, as deﬁned by CR + HI using IWG  2006 criteria, was  achieved
y 8/10 patients, all 8 of who were correctly matched using the
omputational biology modeling system; yielding a test sensitivity
f 100% (p = 0.022) [15]. The 2 patients who did not respond to AZA
nd LEN treatment were also correctly matched using the computer
odeling system, yielding a test speciﬁcity of 100%. Therefore, the
omputational biology PPV and the NPV for this higher-risk MDS
atient cohort treated with AZA and LEN was 100%.
Fig. 4B shows a simpliﬁed schematic of a positively predicted
esponder to AZA and LEN treatment with mutations in TET2,
DH1/2, SRSF2,  and other cytogenetic abnormalities. AzacitidineMA  treatment. This patient shows a loss of ASXL1 and TET2, which reduces PRC2
t shows overexpression of GGH, which inhibits S-adenosyl methionine synthesis
efﬁcacy is facilitated by DNMT mediated CpG methylation and
lenalidomide is dependent on inhibition of NFkB dominance, trans-
lation and activation of TP53. The responder patient schematic
shows overexpression of DNMT1 and CDH1 with a knockdown of
TET2, indicating sensitivity to azacitidine treatment. Additionally,
overexpression of CARD11, STK11, TP53, STUB1 and IRF7 indicated
sensitivity to lenalidomide treatment. Notably, increased activity
of TP53, BAX and BBC3 favor apoptotic pathways targeting MDS
cells.
In contrast, Fig. 4C shows a simpliﬁed schematic of a cor-
rectly matched non-responder with no gene mutations, but who
harbors abnormalities of chromosome 5, 7, and other aberra-
tions. This patient showed signiﬁcantly greater knockdown of
key proteins needed for AZA and LEN treatment efﬁcacy. Knock-
down of DNMT3B, E2F1, MAT2B, and CDH1 indicated resistance
to azacitidine through downregulation of the target methylation
pathway. Knockdown of STUB1, IKZF1/3, APC, AXIN1, CAV1, TSC2,
PRKCB, HIPK2, CARD11, CDH1, and CTNNA1 indicated resistance to
lenalidomide through weakened targets of therapy and strength-
ening of the beta-catenin resistance loop. The combination of these
6 L. Drusbosky et al. / Leukemia Research 52 (2017) 1–7
Fig. 4. Two simpliﬁed schematics of a correctly predicted responder and non-responder from HMA  and Lenalidomide treated high-risk MDS  patients.
Schematic of patients included in cohort 3, with 10/36 patients being modeled. 8/10 patients responded to HMA  + lenalidomide treatment with 8/8 correctly predicted, giving
our  modeling system a test sensitivity of 100%. 2 patients did not respond to HMA  + lenalidomide treatment with 2/2 correctly predicted, giving our modeling system a test
speciﬁcity of 100%. PPV and NPV in cohort 3 is 100%. Overall test speciﬁcity in cohort 3 is 100%. B. Simpliﬁed schematic of dysregulated protein networks in a positively
predicted responder to azacitidine + lenalidomide treatment. Red lines show knockdown in patient proteins, dark red lines show knockdown from treatment, blue lines show
positive  effects and black lines are normal protein networks. Azacitidine efﬁcacy is facilitated by DNMT mediated CpG methylation and lenalidomide is dependent on inhibition
of  NFkB dominance, translation and activation of TP53. This patient schematic shows over expression of DNMT1 and CDH1 with a knockdown of TET2, indicating sensitivity
to  azacitidine treatment. Additionally, overexpression of CARD11, STK11, TP53, STUB1 and IRF7 indicate sensitivity to lenalidomide treatment. C. Simpliﬁed schematic of
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aysregulated protein networks in a correctly predicted non-responder to azacitidin
f  key proteins needed for treatment efﬁcacy. Knockdown of DNMT3B, E2F1, MAT
AV1, TSC2, PRKCB, HIPK2, CARD11, CDH1, CTNNA1 indicate resistance to lenalidom
rotein–protein network aberrations was predicted to result in
esistance to both AZA and LEN treatment.
. Discussion
In this study we show the feasibility of using computer-
odeling capabilities to map  the MDS  mutanome and mathemat-
cal simulations to predict drug response. We  showed that the
ncorporation of chromosomal abnormalities, copy number vari-
tions, and gene mutations from each patient’s MDS  culminates
n a unique nexus of dysregulated protein networks, which can be
sed for simulating drug treatments. Using data from three pub-
ished clinical trials, our computational biology method accurately
atched clinical response in 80–100% of patients, which was higher
han would be expected from empiric prescription of chemothera-
ies. The test speciﬁcities of each cohort ranged from 44%-100%.
his range in speciﬁcity may  be due to small sample sizes, the
imited genomics datasets available, and the small mutation panel
tilized in the LEN and HMA  cohorts.
This technology represents an improvement upon conventional
ttempts to identify patient responders and non-responders. Inves-alidomide treatment. This patient shows signiﬁcantly more knockdown expression
H1 indicate resistance to azacitidine. Knockdown of STUB1, IKZF1/3, APC, AXIN1,
tigators have used large datasets and multivariable regression
analyses to identify single gene abnormalities, such as muta-
tions in TET2 or DNMT3A, that are associated with response to
HMAs or lenalidomide [19–21]. Whereas these one-gene/one-drug
retrospective studies are vitally important in building the base
framework in disease modeling, we show that a method incor-
porating all known genomic abnormalities and their interactions
within individual MDS  patients is capable of faithfully simulating
drug response. More speciﬁcally, we  show that patients whose MDS
harbors a single gene mutation predictive of response may  also har-
bor uncooperative gene mutations that portend drug resistance.
Thus, our results support a multidimensional simulation method
when interpreting the malignant mutanome. This data is consistent
with previous reports of using predictive simulation technology to
create personalized therapeutics [13].
Our technology also identiﬁed novel biomarkers worthy of fur-
ther exploration, and expands upon a previous study using reverse
phase protein array and computational modeling to investigate
the complex role of p38 MAPK mechanisms involved in MDS
pathogenesis [22]. For instance, GGH overexpression was  identi-
ﬁed in one MDS  patient as one of the resistance factors responsible
for HMA  drug resistance (Fig. 3C). GGH catalyzes the hydroly-
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[26] C.C. Bjorklund, W.  Ma,  Z.Q. Wang, R.E. Davis, D.J. Kuhn, S.M. Kornblau, et al.,L. Drusbosky et al. / Leuk
is of anti-folylpoly-gamma-glutamates, removing gamma-linked
olyglutamates, and functions to inhibit S-adenosyl methionine
ynthesis required for methyl group transfers [23]. The loss of
GH function was predicted to inactivate azacitidine’s targeted
ethylation pathways. Activated GGH represents a novel candi-
ate biomarker of resistance to HMAs that is worthy of further
xamination, and adds rigor to the modeling software’s abil-
ty to identify disease-relevant biomarkers [24,25]. Furthermore,
his ﬁnding warns against combining anti-folates with HMAs in
DS  patients with wild type GGH. Another biomarker suggestion
as lenalidomide’s paradoxical activation of beta-catenin, a noted
esistance factor, through lenalidomide’s inhibition of CSNK1A1.
he CSNK1A1 kinase is part of the beta-catenin destruction com-
lex that phosphorylates and induces proteasomal degradation of
eta-catenin. Therefore inhibition of CSNK1A1 results in increased
evels of beta-catenin, strengthening the resistance loop against
enalidomide [26]. This ﬁnding demonstrates the pivotal regula-
ory role of beta-catenin in lenalidomide response. Further studies
f the beta-catenin destruction complex may  provide insight into
he beta-catenin resistance mechanism and clinical outcomes in
atients with an altered complex. Thus, through computational
rotein network mapping it is possible to trace the paths for poten-
ial targets of therapy as well as to better understand the cancer
hysiology of MDS  and its potential treatments.
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